Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital filed on March 5, 2020.; Petitioner seeks a Declaratory Statement from the Board as to whether its intended pharmacist involvement in a penicillin skin testing program is appropriate ...

 

DEPARTMENT OF HEALTH

Board of Pharmacy

RULE NO.:RULE TITLE:

64B16-27.810Prospective Drug Use Review

64B16-27.830Standards of Practice - Drug Therapy Management

NOTICE IS HEREBY GIVEN that the Board of Pharmacy has received the petition for declaratory statement from Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital filed on March 5, 2020.The petition seeks the agency's opinion as to the applicability of Rules 64B16-27.830 and 64B16-27.810, F.A.C., as it applies to the petitioner.

Petitioner seeks a Declaratory Statement from the Board as to whether its intended pharmacist involvement in a penicillin skin testing program is appropriate under the auspices of the Drug Therapy Management Rule, 64B16-27.830, F.A.C., and the Prospective Drug Utilization Review Rule 64B16-27.810, F.A.C. Except for good cause shown, motions for leave to intervene must be filed within 21 days after the publication of this notice.

A copy of the Petition for Declaratory Statement may be obtained by contacting: Jessica Sapp, Executive Director, Board of Pharmacy, 4052 Bald Cypress Way, Bin C08, Tallahassee, Florida 32399-3258 or by email at [e-mail].